The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://agnesspov536651.worldblogged.com/45064853/retatrutide-vs-tirzepatide-a-comparative-analysis